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ABSTRACT
 T cells are a unique and minor T-cell subset that differs from conventional  T cells by virtue of their
tissue localization and antigen processing requirements. We have previously shown that ex vivo–activated
T cells are able to prevent graft rejection without causing clinically significant graft-versus-host disease
(GVHD). In the present study, we examined how  T cells facilitate alloengraftment and to what extent
mechanisms used by conventional  T cells are also used by  T cells. We observed that, unlike  T cells,
for which CD8 T cells are primarily responsible for facilitating engraftment, purified CD8 T cells
administered at the same fractional dose as for the unseparated activated T-cell population were insufficient
to prevent graft rejection. Furthermore, the ability to prevent graft rejection was not affected by the absence
of fully functional fas ligand or perforin cytotoxic pathways, nor was it contingent on the ability of  T cells
to recognize recipient major histocompatibility process alloantigens. Repetitive infusions of a suboptimal dose
of  T cells however were able to rescue mice from graft rejection, suggesting that the persistence of these
cells in vivo was critical in facilitating alloengraftment. These studies demonstrate that  T cells do not use
mechanisms used by conventional nontolerant  T cells to prevent graft rejection. The ability of these cells
to promote engraftment without causing GVHD further distinguishes these cells from  T cells and may be
an attribute that can be exploited in the clinical transplantation setting.
© 2006 American Society for Blood and Marrow Transplantation
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Donor T cells are the major cell type responsible
or preventing graft rejection in allogeneic marrow
ransplant recipients. This preventive effect is thought
o result primarily from the direct recognition of al-
oantigens on recipient cells [1-3], although T cells
hat are tolerant of host antigens can also prevent graft
ejection [4-6], albeit with less potency. Previous stud-
es have shown that CD8 T cells are the major 
-cell subset in donor grafts responsible for promot-
ng engraftment [7], and that speciﬁc cytotoxic path-
ays, such as those involving perforin and fas ligand,
re used by these cells to execute their effector func-
ions [8,9]. However, the same cells that are capable of
acilitating donor engraftment are also capable of
ausing graft-versus-host disease (GVHD). And clin-
cal efforts to dissociate these cells’ engraftment-pro-
oting capability from their ability to cause GVHD
ave been largely unsuccessful [10]. This has been the pmpetus for exploring alternative approaches focusing
n the transplantation of larger doses of stem cells [11]
r of T-cell subpopulations other than conventional
 T cells [12-14].
 T cells are one such subpopulation that com-
rise a small percentage of T cells present in the
eripheral blood and secondary lymphoid organs of
ice and humans. We have examined the role of these
ells in promoting donor engraftment and found that
hey are capable of facilitating engraftment across the
ajor histocompatibility complex (MHC) [15]. More-
ver, transplantation of doses of  T cells that are
ble to prevent graft rejection does not cause discern-
ble GVHD [16]. Although these cells share similari-
ies with  T cells in that both differentiate primarily
n the thymus, have common cell surface markers,
ave a diversity of clonotypic receptors associated with
he CD3 complex, and secrete some of the same lym-
hokines [17-19], the manner in which they recognize
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S. Vodanovic-Jankovic and W. R. Drobyski1126ntigens is very distinct [20]. This raises the question
f how  T cells facilitate alloengraftment and to
hat extent the mechanisms used by conventional 
cells are also used by  T cells. The purpose of the
resent studies was to address these questions, with
peciﬁc emphasis on whether  T cells require func-
ional perforin and fas ligand cytotoxic pathways and
o what degree prevention of graft rejection is contin-
ent on the direct recognition of recipient alloanti-
ens by these cells.
ATERIALS AND METHODS
ice
C57BL/6 (H-2b), B6  T-cell–deﬁcient (T cell
eceptor /), B6 perforin–deﬁcient (B6-pfp/),
6 fas ligand–deﬁcient (B6Smn.C3-Tnfsf6gld) (B6-
ld), and AKR/J (H-2k) mice were purchased from
ackson Laboratories (Bar Harbor, ME). Perforin-
eﬁcient (pfp/)  T-cell double-deﬁcient mice
ere produced by breeding B6-pfp/ mice with T-
ell receptor (TCR) / mice. Offspring were then
ntercrossed and screened by polymerase chain reac-
ion (PCR) for the presence or absence of the perforin
ene and by ﬂow cytometry to detect  T cells. The
ild-type pfp gene yields a 300–base pair (bp) prod-
ct, whereas the mutant gene results in a 665-bp
roduct, allowing for discrimination after gel electro-
horesis [21]. Fas ligand–deﬁcient TCR / dou-
le-deﬁcient mice were constructed by breeding B6-
ld mice with TCR / mice. Offspring were
ntercrossed as described earlier and screened by PCR
nd ﬂow cytometry. The wild-type and gld genes were
mpliﬁed using previously described primer sequences
8]. TCR / mice on an AKR background were
ade by backcrossing B6 TCR / mice with nor-
al AKR mice. Offspring after each backcross were
creened by PCR for the presence of the neomycin
ene, which is in the targeting cassette used to create
CR / mice [22]. After 5 generations, mice that
ere heterozygous for the  TCR mutation were
ntercrossed and screened by ﬂow cytometry for ab-
ence of  T cells. AKR TCR /mice were then
red to B6 TCR / mice to create B6  AKR F1
CR / mice. All mice were housed in the Amer-
can Association for Lab Animal Care –accredited An-
mal Resource Center of the Medical College of Wis-
onsin. The mice received regular mouse chow and
cidiﬁed tap water ad libitum. Experiments were con-
ucted following Medical College of Wisconsin Ani-
al Research Center–approved protocol.
x Vivo Activation and Expansion of Murine
 T Cells
To expand  T cells, spleen cells were obtained
rom TCR / donor mice and passed through iylon wool columns to remove B cells. The cells were
hen resuspended in complete Dulbecco’s modiﬁed
ssential medium (CDMEM) plus 5%–10% fetal bo-
ine serum and cultured in ﬂasks precoated with an
mmobilized  T-cell–speciﬁc monoclonal antibody
GL4, hamster IgG; BD Biosciences, San Jose, CA) at
concentration of 5 g/mL. Then 24 hours after the
nitiation of culture, human interleukin (IL)-2 (Pro-
eukin; Chiron, Emeryville, CA) was added at a con-
entration of 100 IU/mL. All cultures were split into
resh ﬂasks as needed to maintain a cell concentration
f 0.5–1.5  106 cells/mL. The cells were exposed to
mmobilized monoclonal antibody for the ﬁrst 3–4
ays of culture and thereafter grown only in medium
lus 100 IU/mL of IL-2 to allow for reexpression of
he  TCR. After a total of 7–8 days in culture, the
ells were counted and the percentage of  T cells
as analyzed by ﬂow cytometry. Routinely, 5–10 
08 cells were obtained after expansion, with 95%–
9% of cells expressing the  TCR. Typically, 15%–
5% of activated  T cells coexpressed CD8. CD4
xpression was not detected on these cells. In some
xperiments, puriﬁed CD8  T cells were obtained
y positive selection of spleen cells from TCR /
ice using the Miltneyi MACS separation system
Miltenyi Biotec, Auburn, CA), followed by activation
nd expansion of these selected cells using GL4 anti-
ody and IL-2, as described earlier.
ctivation and Expansion of B Cells
Spleen cells from TCR / donor mice were
rocessed into single-cell suspensions and then cul-
ured for 72 hours in 4 g/mL of lipopolysaccharide
Sigma, St. Louis, MO). After 3 days in culture, cells
ere then admixed with T-cell–depleted (TCD) bone
arrow (BM) for transplantation into recipient mice.
n 2 experiments, 90%–93% of cells were B220/NK
.1 after expansion, whereas in the third experiment,
3% of activated cells had this B-cell phenotype.
one Marrow Transplantation
BM was ﬂushed from donor femurs and tibias with
DMEM and passed through sterile mesh ﬁlters to
btain single-cell suspensions. BM was T-cell de-
leted in vitro with anti-Thy1.2 monoclonal antibody
lus low-toxicity rabbit complement (C6 Diagnostics,
equon, WI). The hybridoma for 30-H12 (anti-
hy1.2, rat IgG2b) antibody was obtained from the
merican Tissue Culture Center (Rockville, MD) and
rown in CDMEM plus 5% fetal bovine serum. The
ulture supernatants were then harvested, precipitated
n ammonium sulfate, and dialyzed against phosphate-
uffered saline before use in the in vitro depletion
xperiments. BM cells were then washed and resus-
ended in CDMEM before injection. To recover na-
ve T cells, spleen cell suspensions were obtained by
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 T Cells and Prevention of Graft Rejection 1127ressing spleens through wire mesh screens. Erythro-
ytes were removed from cell suspensions by hypo-
onic lysis with sterile distilled water. AKR/J recipient
ice were given sublethal total body irradiation (800
Gy) as a single exposure at a dose rate of 70 cGy
sing a Shepherd Mark I Cesium Irradiator (JL Shep-
erd and Associates, San Fernando, CA). Irradiated
ecipients then received an intravenous injection of
CD BM (10  106) with or without ex vivo–acti-
ated  T cells or B cells. When a dose of 150  106
ctivated  T cells or B cells was administered to
ecipients, the total dose was split into thirds and
iven over a 24-hour period. This was done to reduce
mmediate toxicity from the infusion of a large num-
er of activated cells.
low Cytometric Analysis
Monoclonal antibodies conjugated to either ﬂuo-
escein isothiocyanate (FITC) or phycoerythrin (PE)
ere used to assess chimerism in marrow transplant
ecipients. FITC anti-Thy1.2 (clone 30-H12, rat
gG2b) was purchased from Collaborative Biomedical
roducts (Bedford, MA). PE anti-CD8 (clone CT-
D8a, rat IgG2a) was obtained from Caltag (San
rancisco, CA). PE anti-TCR  (clone H57-597,
amster IgG), PE-anti-CD45R (B220, clone RA3-
B2, rat IgG2a), PE anti-TCR  (clone GL3, ham-
ter IgG), PE anti-CD3 (clone 145-2C11, hamster
gG), PE anti-CD4 (clone GK 1.5, rat IgG2b), and
ITC anti–H-2Kb (clone AF6-885, mouse IgG2a)
ere all purchased from BD Biosciences. Spleen and
hymus cells were obtained from chimeras at deﬁned
ntervals posttransplantation and stained for 2-color
nalysis. Red blood cells were removed from spleens
y lysis in distilled water. Cells were analyzed on a
ACScan ﬂow cytometer (Becton-Dickinson, Moun-
ain View, CA). Splenic T-cell chimerism was assessed
ithin a lymphocyte-gated population, whereas over-
ll donor and thymic chimerism were evaluated using
pen gates. At least 10,000 cells were analyzed for
ach determination whenever possible.
able 1.  T Cells Facilitate Donor Splenic and Thymic Engraftment
Group
Number
of Mice
Splee
Spleen
Size (106)
Perce
Donor T
CD 13 30  2 8 
 T Cells 12 49  8 46 
ublethally irradiated AKR mice (800 cGy) were transplanted with
T cells from TCR / mice. Animals were sacriﬁced 26–36 d
donor chimerism. Splenic donor T cells were deﬁned as Thy1.2
are presented as mean 	 SEM and are the cumulative results
chimerism which was obtained from two of the four experimen
P  0.001.
P  0.01.tatistics
Group comparisons of T-cell and donor chimer-
sm in the spleen and thymus, splenic cellularity, and
hymic size were performed using the Mann-Whitney
test. A 2-tailed P value .05 was deemed signiﬁcant
n all experiments.
ESULTS
Transplantation with  T cells prevents graft
ejection and enhances donor thymic engraft-
ent. Initial studies were performed to examine the
ffect of transplantation of ex vivo–activated T cells
n both splenic and thymic engraftment. Sublethally
rradiated (800 cGy) AKR/J mice underwent trans-
lantation with TCD B6 BM alone or together with
50  106 ex vivo expanded  T cells. This number
f  T cells used was based on previous studies
howing this dose to be optimal for facilitating donor
ngraftment in the spleen [15]. Mice that underwent
ransplantation with TCD BM alone uniformly re-
ected their grafts and had no thymic engraftment
ith BM-derived donor T cells (Table 1). Conversely,
ransplantation with activated  T cells signiﬁcantly
nhanced donor T-cell and overall donor engraftment
Table 1). The majority of splenic donor T cells in
ice that underwent transplantation with  T cells
xpress the  TCR 3-4 weeks post-BMT [16]. Be-
ause these cells must be BM-derived  T cells that
ave emerged from the thymus, we also examined
hymic engraftment in mice that underwent transplan-
ation with  T cells. Due to the fact that the vast
ajority of T cells do not express CD4, we assessed
he percentage of donor-derived CD4 T cells in the
hymus of these mice as a marker for reconstitution of
M-derived  T cells. Mice that underwent trans-
lantation with  T cells had a signiﬁcantly higher
ercentage of donor CD4 T cells than the control
ice (Table 1), conﬁrming that  T cells enhanced
ngraftment of BM-derived T cells.
Thymus
Percent
Donor Cells*
Thymus
Size (106)
Percent Donor
CD4 Cells†
11  3 58  14 1  0
65  10 113  22 59  16
B6 BM (10  106) alone or together with 150  106 activated 
st transplantation and analyzed for the extent of splenic and thymic
, while donor thymocytes were deﬁned as Thy1.2 CD4. Data
four independent experiments, except for the data on thymocyte
8 mice per group).n
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8
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S. Vodanovic-Jankovic and W. R. Drobyski1128Enhanced engraftment by  T cells is not due
o nonspecific cold-target inhibition. The require-
ent for large doses of  T cells observed in these
xperiments and previous studies [15,16] raised the
uestion of whether facilitation of alloengraftment
as attributable to a cold-target inhibition effect that
ould be operative regardless of cell type. To exclude
his possibility, we performed 3 independent experi-
ents in which mice underwent transplantation with
n equivalent number of lipopolysaccharide-activated
cells. Mice that received TCD BM alone all rejected
heir grafts (n 
 10; mean percent splenic donor T
ells, 4% 	 2%), as expected. Addition of an equiva-
ent number of activated B cells (150  106) to the
arrow graft however, did not increase donor T-cell
ngraftment or prevent rejection (n
 9; mean percent
onor T cells, 1% 	 0). These data indicate that the
ngraftment-facilitating effect of  T cells is not
olely a function of cell number, but is also directly
ttributable to cell type.
CD8 T cells alone are insufficient to pre-
ent graft rejection. Previous studies have shown
hat CD8 T cells are the  T-cell subpopulation
rimarily responsible for preventing graft rejection
7]. Whereas the majority of  T cells are CD4
D8, CD8 T cells do compose approximately
igure 1. CD8 T cells alone are insufﬁcient to prevent graft re
pleen of TCR /mice (A), after positive selection using CD8-s
ith GL4 monoclonal antibody and IL-2 for 6–8 days as described
Gy) underwent transplantation with TCD B6 BM (10  106) alon
CR / mice (; n 
 9). Mice were sacriﬁced 64 days posttran
ata are presented as the mean 	 SEM and are the cumulative re5%–25% of  T cells in the spleens of TCR / Bice (Figure 1A). Consequently, we performed exper-
ments to determine whether this population was re-
ponsible for preventing graft rejection. Of the 150 
06 activated  T cells transplanted into murine re-
ipients, CD8 T cells represented on average
3-38  106 cells. Consequently, we used a dose of
0  106 CD8 T cells to approximate the num-
er of  T cells that the mice received in unseparated
nfusions. CD8 T cells were ﬁrst puriﬁed by
ositive selection from TCR / spleen cells (Fig-
re 1B) and then expanded for 6-8 days as described in
aterials and Methods, to yield a pure population of
D8 T cells (Figure 1C). Sublethally irradiated
KR mice then underwent transplantation with TCD
6 BM alone or together with puriﬁed CD8 T
ells. All of the mice that underwent transplantation
ith TCD BM only rejected their grafts when exam-
ned 64 days post-BMT (mean percent donor T cells,
% 	 2%) (Figure 1D). Adding 30  106  T cells
o the TCD marrow grafts failed to increase donor
-cell engraftment above control levels (4% 	 4%),
ndicating that the CD8 component of the expanded
 T-cell population was not solely responsible for
reventing graft rejection.
Alloengraftment mediated by  T cells does
ot require expression of perforin or fas ligand.
. (A-C) Dot plots showing the percentage of CD8 cells in the
magnetic beads (B), and after expansion of CD8-enriched  T cells
terials and Methods (C). (D) Sublethally irradiated AKR mice (800

 7) or together with 30  106 activated CD8  T cells from
tion and analyzed for the extent of splenic donor T-cell chimerism.
2 experiments.jection
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 T Cells and Prevention of Graft Rejection 1129mportant in preventing graft rejection by donor  T
ells [8,9]. We examined the role of these pathways
sing  T cells obtained from TCR / mice that
ere also either perforin or fas ligand deﬁcient. In
nitial experiments, AKR mice underwent transplan-
ation with TCD BM alone or with either 150  106
ild-type or perforin-deﬁcient  T cells. Animals
ere sacriﬁced 59-75 days post-BMT and assessed for
onor T-cell and overall donor engraftment in the
pleen. Mice that underwent transplantation with ei-
her perforin-deﬁcient or wild-type  T cells had
igniﬁcantly greater donor T-cell (Figure 2A) and/or
verall donor engraftment (Figure 2B) compared with
nimals that underwent transplantation with TCD
M alone. However, there was no statistically signif-
cant difference in either donor T cell engraftment
46% 	 13% vs 56% 	 15%; P 
 .59) or overall
onor cell engraftment (49% 	 15% vs 55% 	 15%;

 .65) between the mice that underwent transplan-
ation with perforin-deﬁcient or wild-type  T cells,
espectively (Figure 2). Subsequent experiments were
hen performed to determine whether the absence of
as ligand on  T cells adversely affected these cells’
bility to promote engraftment. Sublethally irradiated
KR mice underwent transplantation with TCD BM
lone or together with 150  106 fas ligand–deﬁcient
 T cells. Transplantation with fas ligand–deﬁcient
 T cells resulted in statistically higher donor T-cell
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TCD BM
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Wild Type
igure 2.  T cells are able to facilitate donor engraftment in the a
ransplantation with TCD B6 BM (10 106) alone (white bar; n
 9
erforin deﬁcient (gray bar; n 
 9) or wild-type TCR / (black
nalyzed for the extent of donor T-cell (A) and overall donor chim
he cumulative results of 3 experiments. One mouse that underwen
efore demise. This mouse rejected its graft with  2% donor T ce
003; TCD BM versus wild-type, P
 .08. Percent overall donor; TCDnd overall donor engraftment compared to that seen †n control animals (Table 2). The engraftment of
M-derived  T cells in the thymus was also signif-
cantly higher in these mice. Notably, the extent of
onor engraftment was equivalent to that observed
hen  T cells from wild-type TCR / were
sed (Table 1; Figure 2). Collectively, these data in-
icated that absence of either perforin or fas ligand did
ot adversely affect the ability of T cells to facilitate
lloengraftment.
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gether with 150 106 activated  T cells from either TCR /
8) mice. Mice were sacriﬁced 59–75 days posttransplantation and
B) in the spleen. Data are presented as the mean 	 SEM and are
lantation with perforin-deﬁcient  T cells was analyzed at day 21
istics: Percent donor CD3; TCD BM versus perforin-deﬁcient, P

rsus perforin-deﬁcient, P
 .004; TCD BM versus wild-type, P
 .03.
able 2.  T Cells Do Not Require Fas Ligand Expression to
acilitate Donor Engraftment
Group
Number
of Mice
Percent
Donor
Splenic
T Cells
Percent
Donor
Splenic
Cells†
Percent Donor
Thymic CD4
Cells†
CD 8 3  1 4  1 0  0
ld 11 67  11 72  12 76  12
ublethally irradiated AKR mice (800 cGy) underwent transplan-
tion with TCD B6 BM (10  106) alone or together with 150 
106 activated  T cells from TCR / fas ligand deﬁcient
mice. Mice were sacriﬁced 61–76 days posttransplantation and
analyzed for the extent of donor T-cell and overall donor chi-
merism in the spleen and donor CD4 T-cell engraftment in
the thymus. Data are presented as the mean 	 SEM and are the
cumulative results of two independent experiments.
P 
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S. Vodanovic-Jankovic and W. R. Drobyski1130Engraftment mediated by  T cells is not
ependent on direct recognition of MHC alloan-
igens. Nontolerant  T cells promote engraftment
hrough the recognition and subsequent elimination
f host immune cells. To determine whether engraft-
ent mediated by  T cells was contingent on the
irect recognition of recipient alloantigens, we used
CR / B6  AKR F1 mice as donors, because
 T cells from these mice are tolerant of and thereby
nable to recognize host (AKR) MHC antigens. Sub-
ethally irradiated AKR mice underwent transplanta-
ion as before with TCD BM alone or together with
50  106 activated  T cells from  T-cell–deﬁ-
ient B6  AKR F1 mice. In the control mice, donor
-cell and overall donor chimerism averaged 10%
Figure 3). In contrast, animals that underwent trans-
lantation with  T cells from F1 donors had a
igniﬁcantly higher percentage of donor T-cell en-
raftment (42% 	 9%; P 
 .0002) and overall donor
ngraftment (47% 	 9%; P 
 .002) than control
ice. The extent of engraftment approximated that
een after transplantation of  T cells from TCR
/ mice (Table 1). Thus, recognition of recipient
HC alloantigens was not a prerequisite for the en-
raftment-promoting effect of  T cells.
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igure 3. Engraftment mediated by  T cells is not dependent on
ecognition of recipient MHC alloantigens. Sublethally irradiated
KR mice (800 cGy) underwent transplantation with TCD B6 BM
10  106) alone (□; n 
 25) or together with 150  106 activated
 T cells from TCR / B6  AKR F1 (; n 
 23) mice. Mice
ere sacriﬁced 63–76 days post transplantation and analyzed for the
xtent of donor T-cell (CD3) and overall donor (donor) chimerism
n the spleen. Data are presented as the mean 	 SEM and are theoumulative results of 7 experiments.Repetitive infusions with suboptimal doses of
 T cells rescue mice from graft rejection. In
hese and previous studies [15], we observed that pre-
ention of graft rejection was contingent on adminis-
ration of high doses of  T cells, and that doses 
50  106 were much less effective in promoting
onor engraftment. We reasoned that the require-
ent for large cell doses to achieve durable engraft-
ent might be attributable to the limited in vivo
urvival of  T cells after withdrawal from IL-2. To
est this premise, we examined whether repetitive in-
usions of suboptimal doses of  T cells could rescue
ice from graft rejection. To conﬁrm our earlier
ndings, sublethally irradiated AKR mice underwent
ransplantation with TCD BM alone or with a single
ose of 50  106 activated  T cells at the time of
ransplantation. The mean percentage of donor T
ells in the spleen was 1% in mice receiving TCD BM
lone, whereas animals receiving 50  106  T cells
ad no detectable splenic donor T cells when assessed
8 days posttransplantation, demonstrating that this
ose did not prevent graft rejection. To assess the
ffect of multiple serial infusions, AKR mice then
nderwent transplantation with TCD B6 BM alone or
ogether with 50 106  T cells administered before
MT and then on days 7 and 14 posttransplantation (a
otal of 3 infusions). Transplantation with multiple
oses of  T cells had no differential affect on either
plenic or thymic cellularity (Figure 4A); however,
here were signiﬁcant increases in donor T-cell and
verall donor engraftment in the spleen, as well as
onor T-cell engraftment in the thymus, compared
ith control mice that all rejected their grafts (Figure
B). The degree of donor engraftment in mice that
nderwent transplantation with  T cells was similar
o that observed when the entire cell dose was given
mmediately post-BMT. All mice that were given
ultiple infusions survived until the experiments were
oncluded 64–66 days post-BMT. Their serial weight
urves were indistinguishable from those of control
ice, indicating no clinical evidence of GVHD (Fig-
re 4C). The absolute number of donor splenic B cells
n these mice averaged 37 	 6  106 (n 
 12). This
as further evidence for the absence of GVHD since
ack of B-cell reconstitution is a sensitive indicator for
VHD in this strain combination [23].
ISCUSSION
Donor  T cells play a critical role in preventing
raft rejection after allogeneic stem cell transplanta-
ion, but are also capable of causing GVHD. The ex
ivo activation of these cells reduces, but does not
brogate, the ability of these cells to mediate GVH
eactivity [24]. In contrast, we have previously dem-
nstrated that doses of activated  T cells capable of
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 T Cells and Prevention of Graft Rejection 1131reventing graft rejection do not cause GVHD [16].
onsequently, the purpose of the present study was to
xamine the mechanism(s) by which  T cells facili-
ate alloengraftment and the extent to which these
arallel mechanisms used by conventional  T cells.
We examined whether  T cells required fully
unctional cytotoxic pathways since the establishment
f donor engraftment is contingent on the inactivation
r elimination of host immune cells that can reject the
raft. Previous studies have demonstrated that  T
ells contain perforin and serine proteases, such as
ranzyme A and B [25-27]. Moreover, we have ob-
erved that activated  T cells express fas ligand (data
ot shown), and others have demonstrated that inter-
ctions between CD95L on  T cells with CD95
xpressed on target cells lead to apoptotic cell death
28,29]. Therefore,  T cells have the same cytotoxic
ffector pathways as  T cells. With respect to  T
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igure 4. Repetitive infusions with a suboptimal dose of  T cells
escues mice from graft rejection. (A and B) Sublethally irradiated
KR mice (800 cGy) underwent transplantation with TCD B6 BM
10  106) alone (□; n 
 8) or together with 50  106 activated 
cells from TCR / mice (; n 
 12) on days 0, 7, and 14
osttransplantation (a total of 3 doses). Mice were sacriﬁced 64–66
ays after BMT and analyzed for splenic and thymic cellularity (A)
nd the extent of donor chimerism in the spleen and thymus (B).
C) Serial weight curves of mice that underwent transplantation in
A) and (B). All mice in both groups survived until the termination
f the experiments. Data are presented as the mean 	 SEM and are
he cumulative results of 2 experiments. Statistics: TCD BM
ersus  T cells, spleen cellularity, P 
 .22; thymic cellularity,

 .06; donor T-cell chimerism (spleen), P  .0001; overall
onor chimerism (spleen), P  .0005; donor T-cell chimerism
thymus), P  .0002.ells, the role of cytotoxic pathways, such as perforin cnd fas ligand, in preventing graft rejection has been
valuated primarily for CD8 T cells, because these
ells have been shown to be more critical in prevent-
ng graft rejection than CD4 T cells [7]. The major-
ty of  T cells express neither CD4 nor CD8, how-
ver. Furthermore, we demonstrated that  T cells
hat do express CD8 are not by themselves capable of
reventing rejection when administered in the same
umbers as are present in the bulk population (Figure
). For these reasons, we elected to examine the role of
hese pathways in an unseparated population of acti-
ated  T cells. Our ﬁndings demonstrated that the
bsence of either fas ligand or perforin does not ad-
ersely affect these cells’ ability to promote engraft-
ent (Figure 2; Table 2). The extent of both T-cell
nd overall donor cell engraftment was comparable to
hat observed when wild-type  T cells were used.
here are several possible interpretations of these
ndings. One interpretation is that at least 1 pathway
ust be functional for  T cells to promote alloen-
raftment, but both pathways are not required. An-
ther is that neither pathway is necessary for these
ells to prevent rejection. Whether there is an abso-
ute requirement for at least 1 functional cytotoxic
athway to facilitate alloengraftment remains to be
nvestigated in future studies with donor TCR /
ice that are both perforin and fas ligand deﬁcient.
hese data also do not exclude the possibility that 
cells may induce cytotoxicity independent of either
athway, possibly through cytokine secretion. For ex-
mple, gamma interferon secretion by  T cells has
een shown to be capable of inducing cell death
30,31] and could be a mechanism by which host T
ells capable of rejecting the graft are thereby elimi-
ated.
A major distinction between  and  T cells is
he manner in which they recognize alloantigen. 
cells have been shown to recognize foreign peptides
n the context of either class I or class II MHC mol-
cules. Thus, host-versus-graft and graft-versus-host
esponses initiated by these cells are dependent on
ntigen processing and presentation within the con-
traints of this paradigm. The manner in which 
cells recognize antigen however has been shown to
iffer from that of  T cells. Whereas MHC-re-
tricted  T-cell clones have been reported [32,33],
T-cell populations capable of recognizing nonpoly-
orphic class I–like molecules (eg, class Ib molecules,
urface antigens such as CD1, or heat-shock proteins)
lso have been identiﬁed [34-36]. These studies sug-
est that  T cells may have more ﬂexible antigen-
ecognition requirements. This is corroborated by
tudies demonstrating that  T cells recognize MHC
t a site other that the peptide-binding groove and
hat antigen processing is not required for recognition
20]. In fact, the crystal structure of the  TCR in
omplex with the class Ib molecule T22 has been
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S. Vodanovic-Jankovic and W. R. Drobyski1132etermined, and it has been conﬁrmed that this inter-
ction is distinctly different from that between the 
CR and the MHC-peptide complex [37]. The ab-
ence of these cells in areas that are the primary sites
f antigen presentation (ie, lymph nodes and spleen)
urther supports the premise that  T cells do not
equire professional APCs for antigen presentation. In
hat regard, in humans,  T cells are able to recog-
ize a number of ligands that do not require antigen
rocessing, including nonpeptide prenyl phosphate
ompounds and alkyl amines that are abundant in
acteria [38]. MHC class Ib molecules MICA/MICB,
nduced by heat shock in gut epithelial cells, have also
een shown to be ligands for  T cells [39,40].
lthough no such speciﬁcity for nonpeptide com-
ounds has yet been found in mice, class Ib gene
roducts, such as T10 and T22, have been identiﬁed
s ligands for  T cells [41,42].
This issue is relevant because the prevention of graft
ejection is thought to occur primarily through the direct
ecognition of MHC alloantigenic differences on host T
ells that have survived the conditioning regimen. For
his reason, we evaluated whether  T cells had to
ecognize recipient alloantigens to facilitate engraft-
ent. Our ﬁndings show that T cells that are tolerant
f host antigens are still capable of enhancing donor
ngraftment (Figure 3). Although the direct recogni-
ion of recipient MHC alloantigens has been shown to
e a major mechanism used by donor  T cells to
acilitate alloengraftment, donor T cells that are inca-
able of recognizing host MHC alloantigens can also
acilitate alloengraftment in some cases. Lapidot et al
5] demonstrated that engraftment of MHC-incom-
atible marrow could be enhanced by F1 thymocytes
evoid of graft-versus-host activity, and others have
eported similar results using donor T cells derived
rom radiation chimeras [4]. One postulated mecha-
ism for how these cells prevent graft rejection is a
eto effect whereby the host cytotoxic T lymphocyte
CTL) precursor is eliminated after encounter with
he donor veto cell. Initial studies purported that veto
ctivity is both antigen-speciﬁc and MHC-restricted
nd dependent on the interaction of CD8 molecules
n the veto cell with the 3 domain of class I mole-
ules on host CTL precursors [43,44]. However, re-
ent studies have shown that veto activity is not re-
tricted to CD8 T cells, but is also found in activated
atural killer cells, CD4 T cells, and CD34 cells
6,45-47]. Notably, B cells have not been shown to
ave veto activity [46], and these cells exhibited no
bility to prevent graft rejection in our studies. The
equirement of fas ligand on the veto cell is contro-
ersial. Several studies from Reisner et al [45,48] have
ndicated that veto activity of both speciﬁc and third-
arty CD8 T cells occurs through fas/fas ligand
nteractions; however, earlier studies from Chrobak et
l [49] showed that veto activity mediated by activated fM cells did not require either fas ligand or perforin
xpression. A requirement for activation of the veto
ell to execute veto activity has been demonstrated in
early all studies [45-49], consistent with the ability of
x vivo–activated  T cells to prevent rejection.
hus, a potential mechanism by which  T cells
acilitate alloanegraftment could be through a veto
ffect. The facts that the majority of  T cells are
ouble-negative (CD4CD8) and that puriﬁed acti-
ated CD8  T cells fail to prevent rejection indi-
ate that if these cells do in fact exert a veto effect,
xpression of CD8, perforin, and fas ligand are not
equired.
T cells that are tolerant of recipient alloantigens
ave potential clinical advantages in that these cells
re also unable to cause GVHD. A difﬁculty with the
linical application of this strategy has been that ac-
uisition of tolerant T cells in murine model systems
as been dependent on the creation of hematopoietic
himeras [4], cell sorting of rare T-cell subpopulations
13,14], or the use of F1 hybrid T cells [5]. All of these
pproaches have limitations when extrapolated to the
linical setting. In contrast, technologies for the ex-
ansion of  T cells have been developed that permit
he application of this approach to patients [50,51].
he primary obstacle to date has been the need for
arge cell doses in the murine system to promote
llogeneic engraftment. It has been found that the
elative percentage of  T cells in mouse spleen
eclines signiﬁcantly between post-BMT weeks 2 and
as BM-derived  T cells emerge from the thymus
o become the predominant donor T-cell population
16]. This is likely due to the death of these cells after
ytokine withdrawal and possibly the reestablishment
f homeostatic mechanisms that regulate the percent-
ge of these cells in the host. We postulate that at
ower cell dose levels, the number of  T cells that
urvive throughout the critical engraftment period is
oo low to prevent rejection, possibly due to the ex
ivo culture conditions that limit in vivo survival
nd/or function. Consequently, we evaluated whether
ultiple weekly infusions of a dose that was subopti-
al when administered only once immediately post-
ransplantation could in effect increase the survival of
hese cells during the peritransplantation period.
hese studies showed that administration of the same
umulative dose (ie, 150  106) spread out over 2
eeks resulted in near-complete donor engraftment.
otably, these infusions did not cause clinical GVHD
hen assessed by survival, serial weight curves, or the
xtent of B-cell reconstitution, despite the administra-
ion of cells as late as 2 weeks post-BMT. From a
linical standpoint, these data suggest that strategies
or prolonging survival of T cells during the critical
ngraftment period might allow for cell dose reduc-
ions that would make this approach more clinically
easible. Whereas the administration of multiple infu-
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 T Cells and Prevention of Graft Rejection 1133ions is one option, an alternative approach may be to
se cytokines, such as IL-7, to enhance in vivo survival
f lower doses of  T cells. This strategy has recently
ielded promising results in a murine model of human
euroblastoma [52].
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